Cite
HARVARD Citation
Wang, J. et al. (n.d.). 132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis. Immuno-oncology technology. p. . [Online].